
Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22% decrease between quarters. Horizon Therapeutics earned $326.54 million, and sales totaled $1.04 billion in Q3.